Remission of Tardive Dystonia With Electroconvulsive Therapy

Manteghi, Ali Akhoondpoor; Hojjat, Seyed Kave; Javanbakht, Arash

doi:10.1097/jcp.0b013e3181a6d0a1

Cited by 3 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among 40 patients with tardive dyskinesia, after ECT, 27 of the patients had improvement [6,8,9,[14][15][16][17][18][19][20][21][22][23][24][25], 11 patients remained no change [23,26] and 2 patients presented worsening symptoms [26,27]. Among 16 patients with tardive dystonia, all of them showed improvement after ECT [8,[28][29][30][31][32][33]. As for TT, our case was the only report and presented with improvement after ECT.…”

Section: Discussionmentioning

confidence: 99%

Successful Electroconvulsive Therapy for a 74-year-old Female with Major Depressive Disorder and Tardive Tremor: A Case Report and Literature Review

Yeh

Chiu

Chang

et al. 2020

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

Tardive tremor is an infrequently form of tardive syndrome that is developed from prolonged treatment with dopamine receptor blocking agents. This condition presents as a prominent tremor that may cause significant distress but currently lacks effective treatment. Electroconvulsive therapy (ECT) has been applied to treat tardive syndrome. In this study, we report a 74-year-old female patient with major depressive disorder, whose tardive tremor and depressive symptoms showed remarkable improvement after receiving 10 sessions of ECT treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful Electroconvulsive Therapy for a 74-year-old Female with Major Depressive Disorder and Tardive Tremor: A Case Report and Literature Review

Yeh

Chiu

Chang

et al. 2020

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

show abstract

“…In our case, ECT alleviated symptoms of TDt, and the patient's AIMS score was halved. Although there are limited case reports and series to date, the efficacy of ECT for TDt has been reported previously 3–5 . Therefore, when TDt is refractory to pharmacotherapy, ECT may be considered a treatment option.…”

Section: Discussionmentioning

confidence: 99%

“…Although there are limited case reports and series to date, the efficacy of ECT for TDt has been reported previously. [3][4][5] Therefore, when TDt is refractory to pharmacotherapy, ECT may be considered a treatment option. Yasui-Furukori et al…”

Section: Discussionmentioning

confidence: 99%

“…Although there are limited case reports and series to date, the efficacy of ECT for TDt has been reported previously. 3 , 4 , 5 Therefore, when TDt is refractory to pharmacotherapy, ECT may be considered a treatment option. Yasui‐Furukori et al reported that the response rate to ECT for TDt was 30% in 10 cases with depression or schizophrenia; moreover, AIMS scores were reduced by over 25% in all cases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Improvement in both severe obsessive–compulsive disorder and refractory tardive dystonia following electroconvulsive therapy: A case report

et al. 2022

View full text Add to dashboard Cite

Background: Obsessive-compulsive disorder (OCD) is often resistant to treatment and may be complicated by tardive dystonia (TDt) with the use of neuroleptics. Furthermore, patients with TDt often have an inadequate response to pharmacotherapy. Although electroconvulsive therapy (ECT) is considered a common treatment option for both TDt and OCD, its efficacy has not been well established for either condition.Case Presentation: Our case was a 37-year-old Japanese woman who showed improvement in both refractory TDt and severe OCD following ECT. A total of 12 ECT sessions resulted in an improvement in both diseases. To the best of our knowledge, this is the first report of a case in which ECT was effective for both TDt and OCD. Conclusion:Our report highlights the following two points: when TDt is associated with severe OCD, and the effect of pharmacotherapy is inadequate, ECT may be considered as a treatment option; given the common mechanism of frontal cortex-basal dysfunction reported in both dystonia and OCD, ECT may have an effect on this pathway.

show abstract

Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors

Niemann

Jankovic

2018

Drugs

View full text Add to dashboard Cite

Tardive dyskinesia (TD) encompasses the spectrum of iatrogenic hyperkinetic movement disorders following exposure to dopamine receptor-blocking agents (DRBAs). Despite the advent of atypical or second- and third-generation antipsychotics with a presumably lower risk of complications, TD remains a persistent and challenging problem. Prevention is the first step in mitigating the risk of TD, but early recognition, gradual withdrawal of offending medications, and appropriate treatment are also critical. As TD is often a persistent and troublesome disorder, specific antidyskinetic therapies are often needed for symptomatic relief. The vesicular monoamine transporter 2 (VMAT2) inhibitors, which include tetrabenazine, deutetrabenazine, and valbenazine, are considered the treatment of choice for most patients with TD. Deutetrabenazine-a deuterated version of tetrabenazine-and valbenazine, the purified parent product of one of the main tetrabenazine metabolites, are novel VMAT2 inhibitors and the only drugs to receive approval from the US FDA for the treatment of TD. VMAT2 inhibitors deplete presynaptic dopamine and reduce involuntary movements in many hyperkinetic movement disorders, particularly TD, Huntington disease, and Tourette syndrome. The active metabolites of the VMAT2 inhibitors have high affinity for VMAT2 and minimal off-target binding. Compared with tetrabenazine, deutetrabenazine and valbenazine have pharmacokinetic advantages that translate into less frequent dosing and better tolerability. However, no head-to-head studies have compared the various VMAT2 inhibitors. One of the major advantages of VMAT2 inhibitors over DRBAs, which are still being used by some clinicians in the treatment of some hyperkinetic disorders, including TD, is that they are not associated with the development of TD. We also briefly discuss other treatment options for TD, including amantadine, clonazepam, Gingko biloba, zolpidem, botulinum toxin, and deep brain stimulation. Treatment of TD and other drug-induced movement disorders must be individualized and based on the severity, phenomenology, potential side effects, and other factors discussed in this review.

show abstract

Remission of Tardive Dystonia With Electroconvulsive Therapy

Cited by 3 publications

References 3 publications

Successful Electroconvulsive Therapy for a 74-year-old Female with Major Depressive Disorder and Tardive Tremor: A Case Report and Literature Review

Successful Electroconvulsive Therapy for a 74-year-old Female with Major Depressive Disorder and Tardive Tremor: A Case Report and Literature Review

Improvement in both severe obsessive–compulsive disorder and refractory tardive dystonia following electroconvulsive therapy: A case report

Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors

Contact Info

Product

Resources

About